New drug duo aims to shrink tough lung cancer in 33-patient trial
NCT ID NCT07501169
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, in people with extensive-stage small cell lung cancer whose cancer has already been treated. The goal is to see if the combination can shrink tumors. About 33 adults aged 18 to 75 with good performance status will take part. This is an early-phase, single-arm trial, so there is no comparison group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Sichuan, Chengdu, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Engineered immune cells take on tough lung cancer
- New hope for advanced lung cancer: chemo-radiation combo enters trial
- New hope for aggressive lung cancer: experimental drug combo enters final testing
- New combo therapy shows promise for tough lung cancer
- Promising drug cocktail aims to stall aggressive lung cancer